DSM completes Glycom acquisition

By Jim Cornall

- Last updated on GMT

The acquisition was announced in February, 2020.
The acquisition was announced in February, 2020.

Related tags Dsm Glycom HMO

Royal DSM, a global science-based company in nutrition, health and sustainable living, has completed its acquisition of Danish-headquartered Glycom A/S, the world's leading supplier of Human Milk Oligosaccharides (HMO) for an enterprise value of €765m ($836m).

With the acquisition of Glycom, DSM adds HMOs to its portfolio of nutritional lipids, vitamins and nutrient premixes for the early life nutrition industry.

DSM said the high-growth HMO market is set to deliver novel ingredients for next generation early life nutrition solutions.

Glycom is the only fully-integrated HMO provider in the world with its own product development, preclinical and clinical development, regulatory and large-scale production with an innovation roadmap for next-generation HMOs.

As HMOs are believed essential for the development of immunity, cognitive and digestive functions, there is significant interest in HMOs for the dietary supplement market, unmet medical nutrition needs like irritable bowel syndrome, food and beverage applications and for pet foods.

When the announcement was first made in February, Geraldine Matchett and Dimitri de Vreeze co-CEOs of Royal DSM, said, “We are looking forward to welcoming Glycom to DSM. Our companies have a great fit together, with a shared passion for purpose-led and science-based solutions in Nutrition & Health. This acquisition is an attractive and logical next step for DSM enabling us to provide our customers with innovative Early Life Nutrition solutions in our Human Nutrition business.​”

Related news